Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 12, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions

Refractory Solid Tumor

Interventions

DRUG

177Lu-AB-3PRGD2 radioligand therapy

Radioligand therapy using 177Lu-AB-3PRGD2 80 mCi (2.96 GBq) will be performed 6-weekly. A maximum of 4 cycles will be administered.

Trial Locations (1)

RECRUITING

The First Affiliated Hospital of Xiamen University, Xiamen

All Listed Sponsors

lead

The First Affiliated Hospital of Xiamen University

OTHER